Amgen Inc. shares rose in the extended session Wednesday after the biotech said a late-stage migraine drug study reached its primary endpoint. Amgen shares rose 1.2% to $148.97 after hours. The company said patients given its drug erenumab experienced migraines an average 3.2 to 3.7 fewer days — based on different doses — compared with 1.8 fewer days in the group given a placebo. Patients in the study were suffering an average 8.3 days a month with migraines.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News